FDA Accepts Odronextamab BLA Resubmission for R/R Follicular Lymphoma; Support for the application comes from the efficacy data reported in the phase 1 ELM-1 and phase 2 ELM-2 trials.

Media coverage

• Title	FDA Accepts Odronextamab BLA Resubmission for R/R Follicular Lymphoma; Support for the application comes from the efficacy data reported in the phase 1 ELM-1 and phase 2 ELM-2 trials.
  Media name/outlet	CancerNetwork
  Country/Territory	United States
  Date	26/02/25
  Persons	Tae Min Kim